干细胞之家 - 中国干细胞行业门户第一站

 

 

搜索
朗日生物

免疫细胞治疗专区

欢迎关注干细胞微信公众号

  
查看: 326400|回复: 217
go

A consensus sequence in the endothelin-B receptor second intracellular loop is r [复制链接]

Rank: 1

积分
威望
0  
包包
0  
楼主
发表于 2009-4-21 13:02 |只看该作者 |倒序浏览 |打印
Department of Internal Medicine and the Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas
$ \& a) J9 w) E( i5 O. L! \* m9 v. g2 Y
Division of Biotechnology and Department of Bioscience, National Cardiovascular Center Research Institute, Osaka, Japan4 B/ n2 I8 a% M6 p, Q

: I! g$ \7 e3 W( h& i# T) rABSTRACT
) R* X0 Y. _; V# @. [9 i5 Y$ N7 G1 m5 F! Q$ X3 c& e
Endothelin-1 (ET-1) increases the activity of Na /H  exchanger 3 (NHE3), the major proximal tubule apical membrane Na /H  antiporter. This effect is seen in opossum kidney (OKP) cells expressing the endothelin-B (ETB) and not in cells expressing the endothelin-A (ETA) receptor. However, ET-1 causes similar patterns of protein tyrosine phosphorylation, adenylyl cyclase inhibition, and increases in cell [Ca2 ] in ETA- and ETB-expressing OKP cells, implying that an additional mechanism is required for NHE3 stimulation by the ETB receptor. The present studies used ETA and ETB receptor chimeras and site-directed mutagenesis to identify the ET receptor domains that mediate ET-1 regulation of NHE3 activity. We found that binding of ET-1 to the ETA receptor inhibits NHE3 activity, an effect for which the COOH-terminal tail is necessary and sufficient. ET-1 stimulation of NHE3 activity requires the COOH-terminal tail and the second intracellular loop of the ETB receptor. Within the second intracellular loop, a consensus sequence was identified, KXXXVPKXXXV, that is required for ET-1 stimulation of NHE3 activity. This sequence suggests binding of a homodimeric protein that mediates NHE3 stimulation.
- g) |$ [& {6 m% w7 Q: B
1 Y  C& B" a5 J) r  oopossum kidney cells; endothelin-A/endothelin-B chimeras; sodium/hydrogen antiporter activity0 V6 @# G0 Q  t6 L% V* N' c

6 ~8 H: N3 [  Z6 v: H( P7 STHE ENDOTHELINS (ET) are a family of three 21-amino acid peptides, ET-1, ET-2, and ET-3. They are involved in a variety of physiological responses, such as vascular smooth muscle cell contraction and dilation, development, and regulation of renal function (17, 35). The biological effects of the ETs are mediated by two receptor subtypes, ETA and ETB (3, 13, 32, 34). ET-1 and ET-2 bind the ETA receptor with high affinities, whereas ET-3 binds with low affinity. The three isopeptides bind the ETB receptor with similar high affinities. Both receptors have seven hydrophobic transmembrane domains, characteristic of G protein-coupled receptors. Human ETA and ETB receptors exhibit significant amino acid sequence identity (55% overall, 74% within the putative transmembrane helices) (33, 36). Of the receptor subdomains, the extracellular NH2 terminus and the intracellular COOH-terminal tail display the least sequence similarities, whereas the sequences in intracellular loops 2 and 3 are relatively similar. Despite their similarities, studies have demonstrated distinct roles for these intracellular loops in the human receptors. Human ETA and ETB selectively couple to Gs and Gi, respectively, with the second and third intracellular loops of human ETA involved in Gs activation and the third intracellular loop of human ETB involved in Gi activation (22).
: p1 \7 v1 [) Z# k
6 @! F) U' G5 hET-1 increases the activity of the proximal tubule apical membrane Na /H  antiporter, which mediates the majority of proximal tubular NaCl and NaHCO3 absorption (10, 12, 29, 30). This proximal tubule apical membrane Na /H  activity is mediated by NHE3 (1, 4). OKP cells, an opossum kidney cell line with many proximal tubule characteristics, express NHE3 (2, 23, 24). Using stable transfection, we established OKP cell lines expressing ETA and ETB receptors and showed that in cells expressing the ETB, but not the ETA receptor, ET-1 increases NHE3 activity (7). In addition, NHE3 activation by ET-1 was inhibited by ETB receptor blockers, but not by ETA receptor blockers. Finally, in proximal tubules harvested from ETB receptor knockout mice, ET-1 fails to increase NHE3 activity, whereas stimulation is seen in tubules from wild-type mice (20). These findings agree with immunohistochemistry and binding studies showing that the ETB receptor is the predominant ET receptor on the renal proximal tubule (9, 42). However, the mechanism responsible for the receptor specificity of NHE3 regulation remains unclear. We previously showed that ET-1 causes similar patterns of protein tyrosine phosphorylation, adenylyl cyclase inhibition, and increases in cell [Ca2 ] in ETA- and ETB-expressing OKP cells, implying that an additional signaling pathway must mediate the receptor specificity of NHE3 regulation (7, 8, 28).; D. C" e* a& u

" Y/ y" w8 o- c( G; W& jTo address this, in the current study human ETA/ETB receptor chimeras and site-directed mutagenesis were used to identify the ET receptor domain(s) involved in ET-1 regulation of NHE3 activity in OKP cells. We found that ETA receptor activation inhibits NHE3 activity, an effect for which the COOH-terminal tail is necessary and sufficient. Activation of NHE3 by ET-1 requires the COOH-terminal domain and the second intracellular loop of the ETB receptor. Site-directed mutagenesis within the ETB second intracellular loop identified residues critical for stimulation of NHE3 activity by ET-1. These residues define a consensus sequence, KXXXPKXXXV, required for ET-1 stimulation of NHE3.$ x4 p8 [% c' |

; S/ v- c9 J9 U8 n, U; ?METHODS
5 i9 l6 l% t( p+ ?' \" o/ Q& R6 k% l8 ^, C8 T0 d
Materials. All chemicals were obtained from Sigma (St. Louis, MO) unless otherwise noted as follows. Penicillin and streptomycin were from Whittaker MA Bioproducts (Walkersville, MD); BCECF-AM was from Molecular Probes (Eugene, OR); ET-1 was from Peptides International (Louisville, KY); and 125I-ET-1 was from Amersham (Arlington Heights, IL).# X( p+ a" z( L  c

1 w: Z1 D& n. b7 H/ j! |6 cCell culture and transfections. OKP cells were grown in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C in a CO2 incubator. To overexpress human ETA and ETB receptors, cells were transiently transfected with wild-type, chimera, or mutant receptors using the pME18S expression vector driven by a constitutively active SR promoter (18). OKP cells were plated on coverslips in 35-mm plastic dishes, grown to 80% confluence, transfected with 1.1 μg DNA using Lipofectamine Plus according to the manufacturer's instructions, and grown to 100% confluence. Confluent cells were rendered quiescent by the removal of serum for 24 h before study. Cells on control and experimental coverslips were derived from the same flask and passage and were studied on the same day. ETA/ETB receptor chimeric cDNAs were generated as described (33).( t7 K7 }4 G& n: l) i
! U, h2 `$ S- ]2 u% n
Na /H  antiporter activity. Cell pH was measured in a temperature-controlled spectrofluorometer (SLM 8000C, Rochester, NY) as the ratio of BCECF fluorescence with 500- and 450-nm excitation (emission wavelength 530 nm), as previously described (7, 8, 27, 28). To measure Na /H  antiporter activity, cells were acidified with nigericin and the initial rate of Na-dependent intracellular alkalinization was measured, as previously described (7, 8, 28). In all studies, control and experimental cells were from the same passage and were assayed on the same day. Exposure to 10–8 M ET-1 was begun at the time of BCECF loading (30 min before study). Control cells were exposed to the vehicle (0.1% acetic acid).$ t4 ?) Y. q8 o1 f

8 f6 A6 S1 a1 ^+ fSite-directed mutagenesis. Point mutations were generated using a Stratagene QuikChange Site-Directed Mutagenesis Kit (La Jolla, CA), as per kit protocol. Two primers complementary to each other were designed to contain the desired mutation (Table 1). The plasmid containing the wild-type receptor was grown up in a dam  Escherichia coli strain, resulting in the plasmid DNA methylation. Thermal cycling was performed as per kit instructions (12 cycles of 95°C x 30 s, 55°C x 1 min, and 68°C x 1 min/kb plasmid length) to denature the template, anneal the mutagenic primers, and synthesize the mutation-containing DNA using high-fidelity PfuTurbo DNA polymerase. Dpn1, an endonuclease (target sequence: 5'-Gm6ATC-3') specific for methylated and hemimethylated DNA, was used to digest the methylated, nonmutated parental DNA template. The circular mutated DNA was transformed into XL1-Blue supercompetent cells for nick repair and the DNA isolated by miniprep.
$ }) V1 S# f3 i$ y+ W
9 S1 h$ P9 {  s2 U2 `' C0 zView this table:
& L) ^% C; x5 E/ d% h. [! W) o5 x% J5 K/ v  O0 W; J2 n
Binding experiments. To measure ET-1 binding, cells were grown to confluence in 12-well plates, rendered quiescent, and incubated in medium containing 0.3% BSA and 20 pM 125I-ET-1, ±10–6 M cold ET-1 for 1 h at 37°C. After the binding solution was removed, the cells were washed twice with cold PBS, harvested in 0.5 ml of 1 N NaOH, placed in a scintillation cocktail, and bound ET-1 was counted in a Beckman LS3801 model scintillation counter (Fullerton, CA), as described (7). Nonspecific binding was defined as binding that occurred in the presence of excess (10–6 M) cold ET-1 and was subtracted from total binding (assayed in the absence of cold ET-1) to obtain specific binding. Results are expressed as a percentage of specific binding in cells transfected with the wild-type ETB receptor.( A+ V; v+ I- R8 u( }+ L
6 K3 [: U6 y0 {( M' ~
Statistics. Data are reported as means ± SE. Statistical significance was determined using a paired Student's t-test (NHE3 activity studies) or ANOVA (binding studies) and set at P , m7 k, y, A8 X

/ E0 q. W; D$ v( I' ~RESULTS3 f3 Z' z) z) ]' s9 P1 F
/ h  s& m+ M9 i, c
We previously showed in stably transfected cells that the ET-1-induced increase in NHE3 activity is mediated by ETB and not ETA receptors. The first step of this study was to compare the effect of ET-1 on NHE3 activity in wild-type OKP cells and OKP cells transiently transfected with the ETB or ETA receptor cDNA. In wild-type untransfected cells, 10–8 M ET-1 applied for 30 min caused a consistent small, but statistically insignificant, increase ( 15%) in NHE3 activity (Fig. 1). When the ETB receptor was expressed, 10–8 M ET-1 significantly increased NHE3 activity by 38%, in agreement with our previous study (7). In contrast, in OKP cells expressing the ETA receptor, 10–8 M ET-1 significantly inhibited NHE3 activity (–15%).# l! b3 E, h5 m5 [& ]
& C) {4 s3 t, @: h; E
To identify the domain(s) of the ETB and ETA receptors involved in ET-1 regulation of NHE3 activity, we transfected cells with chimeric ETA and ETB receptor cDNAs. Figure 2 shows the restriction sites used to generate the chimeric cDNAs. Nomenclature will indicate the specific domains derived from each receptor. For example, chimera A(N-III)B(IV-C) designates a chimeric receptor consisting of the ETA sequence from the NH2-terminal extracellular tail to the third transmembrane domain followed by the ETB sequence from the second intracellular loop through the COOH-terminal tail. To generate this chimera wild-type ETA and ETB receptor, cDNA was cut with BssHI (Fig. 2) (33). OKP cells were transiently transfected with each chimeric cDNA and NHE3 activity was measured following exposure to 10–8 M ET-1 or vehicle.: U9 T1 w, \- b/ I0 H! }8 S
& M3 j" P  Y6 S$ l5 P$ A+ \
Role of the COOH-terminal domain. Experiments shown in Fig. 3 examined the role of the COOH-terminal domain. Again, activation of the ETA receptor led to inhibition of NHE3 activity (Fig. 3). Substitution of the ETA COOH-terminal tail with the ETB COOH-terminal tail [A(N-VII)B(C)] prevented this effect, whereas substitution of the ETB COOH-terminal tail with the ETA COOH-terminal tail [B(N-VII)A(C)] mediated inhibition (–26%, P
7 }' b2 u8 X- T# @( q; E, z: X9 e* e' {  H6 z$ Q
By contrast, the above results using the chimera A(N-VII)B(C) suggest that the ETB COOH-terminal domain is not sufficient to mediate stimulation of NHE3 activity by ET-1. The failure of B(N-VII)A(C) to mediate ET-1-induced stimulation of NHE3 could indicate a requirement for the COOH terminus or could be due to ETA-induced inhibition mediated by the ETA COOH terminus. To determine whether the ETB COOH-terminal tail is required for ET-1 stimulation of NHE3, we examined a truncated ETB receptor in which the COOH-terminal tail was removed (18). As shown in Fig. 3, with removal of the COOH-terminal tail ET-1 was without effect on NHE3 activity. Taken together, these results suggest that the ETB COOH-terminal tail is necessary but not sufficient to mediate stimulation of NHE3 activity by ET-1." m0 n$ T2 y( L% _

8 F& X; ^: s- G: J( K& m( ?Role of the ETB receptor intracellular loops. To identify other key domains of the ETB receptor required for ET-1 stimulation of NHE3 activity, we used a series of chimeras in which domains of the ETB receptor were replaced with the corresponding region of the ETA receptor. As shown in Fig. 4, when the ETB sequence extended from the COOH terminus to the third intracellular loop, [A(N-V)B(VI-C) and A(N-IV)B(V-C)], ET-1 had no effect on NHE3 activity. By contrast, when the second intracellular loop of the ETB receptor was included [A(N-III)B(IV-C)], ET-1 stimulation of NHE3 activity was restored ( 35%). These results suggest that in addition to the COOH-terminal tail, a specific region including transmembrane helix III and/or the second intracellular loop of the ETB receptor is required for ET-1 stimulation of NHE3 activity.
- c7 c$ e$ P' x; g2 e
$ D' u7 I( i9 A9 @6 g: BTo confirm this, an additional series of chimeras were used (Fig. 5). When the sequence extending from transmembrane helices III to VI of the ETB receptor was replaced with the corresponding ETA sequence [B(N-III)A(IV-VI)B(VII-C)], ET-1 was without effect on NHE3 activity. When only the region between transmembrane helices V and VI of the ETB receptor was replaced with the corresponding ETA sequence [B(N-IV)A(V-VI)B(VII-C)], ET-1 stimulation of NHE3 activity was restored ( 36%). Together, these data confirm that the domain containing the second intracellular loop and transmembrane helix IV of the ETB receptor is critical in mediating ET-1-induced NHE3 activation.
% T0 K( }6 y; M' _& X! R
, `8 y5 @; {  G6 [& ?$ l6 n* H  aTo further confirm this conclusion, we used a chimera in which both the second intracellular loop and COOH-terminal tail were derived from the ETB receptor and all other intracellular sequences were from the ETA receptor [A(N-III)B(IV-V)A(VI-VII)B(C)]. As shown in Fig. 5, in cells expressing this chimera ET-1 increased NHE3 activity by 35%, confirming that the second intracellular loop and COOH-terminal tail of ETB are both required and sufficient for ET-1 stimulation of NHE3 activity.
  V$ g6 U) M' w6 F  d
# ?) O0 Q( j- @Amino acid residues in the ETB receptor second intracellular loop required for ET-1 stimulation of NHE3 activity. The above studies all confirmed a key role for the domain including the second intracellular loop and transmembrane helix IV in NHE3 stimulation. We reasoned that the key domain was most likely intracellular and further pursued the second intracellular loop. The second intracellular loop is highly conserved with only six amino acids that differ between the ETA and ETB receptors (Fig. 6). The specific role of each of these amino acids was analyzed by site-directed mutagenesis converting each of the six ETB amino acids individually to their corresponding ETA receptor amino acid (Fig. 6 and Table 1). As shown in Fig. 7, in cells expressing wild-type ETB receptor, ET-1 increased NHE3 activity by 46% (P 9 u3 ^; ?% S2 @3 J3 Z4 d2 L1 b( n0 T
0 {' ~1 Y( o) ]& b
The two pairs of K and V residues (K837 and V841; K843 and V847) that were found to be required for ET-1 stimulation of NHE3 activity are each separated by three amino acids. We next tested the role of the six amino acid residues (G838, I839, G840, W844, T845, and A846) lying between the two "K-V" pairs (Fig. 6 and Table 1). W844 is one of the 6 amino acid residues that differs between the ETB and ETA receptors. Mutation of this residue (W844V) had already been shown to have no effect on the ability of ET-1 to stimulate NHE3 activity (Fig. 7). The other five potential X residues were replaced with either a valine or alanine residue. As shown in Fig. 8, individually mutating these residues had no effect on the ability of ET-1 to stimulate NHE3 activity (% stimulation varied between 27 and 52%, P # Y$ u" b# ^1 o) G3 v
3 e1 m, U5 U8 Z9 x& |( t! f
The two KXXXV sequences in the second intracellular loop are separated by a proline that is conserved in ETB and ETA receptors. Mutation of this proline residue (P842) to alanine also prevented ET-1 from stimulating NHE3 activity (Fig. 9). Taken together, these data suggest the presence of a consensus sequence (KXXXVPKXXXV) in the ETB receptor second intracellular loop that mediates ET-1 stimulation of NHE3 activity.# E+ _4 x% _5 v8 l

+ V7 z+ C! G+ o& q; \: z8 W/ _ET-1 binding to receptors. To address the possibility that the varying effect of ET-1 on NHE3 activity in the above studies was a consequence of a difference in receptor expression and/or failure of ET-1 to bind to a mutated receptor, ligand binding studies were performed in wild-type OKP cells and OKP cells expressing intact, and key truncated, chimeric, or mutated receptors in which ET-1 did not stimulate NHE3 activity (Table 2). As shown, specific ET-1 binding was not statistically different between cells expressing the wild-type ETB receptor and those expressing key truncated, chimeric, or mutated receptors.
- a. W7 w& ^+ v; F' ]/ N* R* v  `9 ~8 t! D
View this table:
' H2 o( l9 ^9 i+ V) i) o/ M
) [& V/ H; V6 b. {DISCUSSION7 j1 Y6 D! j8 {/ r, O5 X
& M8 h' h+ W% [, U
The ETs are a family of three conserved 21 amino acid peptides that bind to and mediate their effects through two G protein-coupled receptor subtypes, ETA and ETB (3, 13, 32). Despite significant amino acid homology, the receptors can be pharmacologically distinguished by their affinity for the three ET isopeptides and their distinct physiological roles (22, 26, 36). The ETB receptor mediates release of relaxing factors causing vasodilation and is involved in inflammatory pain, whereas the ETA receptor mediates vasoconstriction, stimulates mitogenesis and matrix formation, is antiapoptotic, and is involved in acute or neuropathic pain (26). Typically, the ETB receptor activates Gi, whereas the ETA receptor activates Gs, but this G protein coupling is not fixed in all cells (22, 36). In the kidney, while both ETA and ETB are present in renal vessels and on tubular epithelial cells, ETB expression predominates in tubular epithelial cells (17, 31, 37).9 r6 k# T* P) N# z  P  _3 N6 a

" A1 G8 N( c9 q, j1 U& e/ @* \We previously showed that ET-1 stimulates NHE3 activity in cultured OKP cells, an effect that is mediated through the ETB and not the ETA receptor (7, 19). ET-1/ETB stimulation of NHE3 activity involves NHE3 phosphorylation and exocytic insertion of NHE3 into the apical membrane (27, 28). As shown in Fig. 1, ET-1/ETA signaling not only fails to stimulate NHE3 activity but inhibits the transporter. The physiological significance of NHE3 inhibition is unclear as ET-1 stimulates the proximal tubule Na /H  antiporter, an effect mediated by the ETB receptor (19, 20).5 C+ e7 c3 O# c. N) x9 u; z' O

8 `; F; `/ k& ~Because of these differing effects on NHE3, we initially sought to determine signaling pathways that were differentially activated by the ETB and ETA receptors in OKP cells. Using inhibitors, we found that NHE3 activation by the ETB receptor was mediated by increases in cell Ca2  and activation of Ca2 -calmodulin kinase and tyrosine kinases. On ET-1 addition, both receptors were found to increase cell Ca2  with patterns that were indistinguishable. In addition, activation of both receptors resulted in tyrosine phosphorylation of proteins with a pattern consistent with focal adhesion protein phosphorylation. Finally, although activation of ETA and ETB receptors can have opposing effects on adenylyl cyclase in many cells, in OKP cells both receptors inhibited adenylyl cyclase (7, 28). These findings led us to hypothesize that an additional signaling pathway must be required for ETB receptor activation of NHE3, perhaps a protein that binds selectively to the ETB receptor. To address this, the present studies were designed to define domains unique to the ETB receptor that were required for NHE3 activation.
( j  ]5 b/ I  F( I- o/ R8 d$ t2 d5 ]3 ^9 S
The ETA and ETB receptors exhibit 55% overall amino acid homology (22, 36). Within the receptor domains, the least homology is seen in the intracellular COOH-terminal domain and the most homology is associated with the transmembrane helices. In addition, intracellular loops, a likely site of protein binding, are highly homologous. In the present studies, OKP cells were transiently transfected with human ETA and ETB receptor chimera as well as mutated ETB receptor cDNAs to determine the domains and sequences responsible for ET-1/ETB stimulation of NHE3. Our laboratory previously showed that we achieve 80% transfection efficiency with transient transfection in OKP cells (14). In addition, we completely inhibited a number of cellular processes in cells transiently transfected with dominant-negative constructs, again suggesting high transfection efficiency (21, 39, 40).
+ c* g, |' w. L6 I4 M
5 a; r+ K* ^5 ~+ rThe studies led to a number of conclusions. First, the COOH-terminal tail of the ETA receptor is necessary and sufficient for inhibition of the NHE3 activity by ET-1. Thus a chimeric receptor that contains only the COOH-terminal tail of ETA, with the remainder of the receptor derived from the ETB receptor, inhibits NHE3. Similarly, an ETA receptor in which the COOH-terminal domain has been replaced with the relevant ETB sequence loses the ability to inhibit NHE3 activity.
) w4 g5 s5 g9 Y; S9 k3 D5 M6 O
+ P7 t, U: L; u7 y# ySecond, the COOH-terminal tail of ETB is required for stimulation of NHE3. Deletion of this sequence eliminates regulation, and replacement with the corresponding ETA sequence leads to ET-1-induced inhibition of NHE3 activity. However, unlike results with the ETA receptor, the COOH-terminal tail is not sufficient for stimulation of NHE3. The chimera containing the COOH-terminal ETB sequence with the remainder of the protein derived from the ETA receptor fails to regulate NHE3 activity. This suggests that in addition to the COOH-terminal tail, at least one other sequence is required for NHE3 activation by ET-1/ETB.
0 O, {  Q. F$ q6 O! y- q1 X6 o9 L( B, {" ?- N7 W0 M, t2 V
The role of the COOH-terminal tail of G protein-coupled receptors has not been studied extensively. In the parathyroid Ca2 -sensing receptor, individual point mutations of His880 and Phe882 in the COOH-terminal tail to alanine residues were associated with decreased total inositol phosphate production and retention of the receptors in the endoplasmic reticulum, suggesting that the COOH-terminal tail is required for efficient targeting of the receptor to the cell surface (6). In the present studies, however, absence of the ETB COOH-terminal tail did not decrease ET-1 binding, demonstrating that trafficking to the plasma membrane had not been impaired.
' r/ R, u" E7 }
. o& M* z- e8 S: P; q* w! eIn addition to a requirement for the COOH-terminal tail, NHE3 activation by ET-1/ETB required a sequence within the second intracellular loop. Comparing a series of chimeras, results consistently demonstrated that the presence of sequences in the second intracellular loop and transmembrane domain IV, between the BssHI and NcoI restriction sites, was required for NHE3 activation. Mutational studies localized the key sequences to the second intracellular loop and further defined the specific sequence required: two essential lysine (K) and two essential valine (V) resides that are spaced as follows: KXXXVPKXXXV (Fig. 6). Both the spacing between the lysine and valine residues and the proline (P) residue were found to be essential to confer ET-1 stimulation of NHE3. The presence of the repeat sequence (KXXXV) and the space requirement for three residues between the K and V pairs suggest that this portion of the receptor may be involved in the binding of a homodimer to the receptor. The presence of the proline residue, typically associated with flexibility in a protein, between the two repeat sequences would also facilitate binding of a homodimer.
& [. z0 x) r7 f  ]9 V
2 M7 V  t* w$ ^3 KThe second and/or third intracellular loops have been shown to be critical for signaling in other G protein-coupled receptors. The second intracellular loop of the thrombin receptor confers specificity to Gq coupling, is hypothesized to be the relevant domain involved in G protein coupling and to mediate conformational changes that prevent or promote G protein coupling in the muscarinic receptor, and is critical for activating the phospholipase C (PLC) pathway through the Gq -subunit in the PTH/PTH-related protein signaling pathway (5, 15, 25, 41). The second and third intracellular loops are involved in inhibiting angiotensin-dependent activation of PLC via the angiotensin 1a receptor (38). The second intracellular loop of the metabotropic glutamate receptor 1 is critical for signal transduction, but unlike most other G protein-coupled receptors, requires cooperation with another intracellular domain (11). In Chinese hamster ovary cells expressing ETA/ETB receptor chimeric proteins, intracellular loops 2 and/or 3 of the ETA receptor mediate ET-1-induced stimulation of cAMP formation, whereas intracellular loop 3 of the ETB receptor mediates ET-1-induced inhibition of cAMP formation, demonstrating that intracellular loops 2 and 3 direct signaling through Gs and Gi, respectively (36). Thus it appears that the intracellular loops of G protein-coupled receptors mediate signal transduction. In the present studies, we show that intracellular loop 2 of the ETB receptor mediates ET-1 stimulation of NHE3 activity., ?/ F& r- s; S! W' ^' m
" u5 f% O9 A9 E& X$ ~$ y' a9 `
The lack of an effect on ET-1 binding to the chimeric and mutated receptors is consistent with studies in COS-7 cells (33). Similarly, the lack of an effect on ET-1 binding with removal of the ETB COOH-terminal tail is consistent with studies from Sakamoto et al. (18) showing that the COOH-terminal tail of the ETB receptor is involved with signaling but not ligand binding. These observations suggest that the tertiary structure of the ETB receptor has been maintained in the chimeric and mutated receptors and that failure of ET-1 to stimulate NHE3 activity is not due to failure of the chimeric or mutated receptors to be expressed on the apical membrane.6 X5 v  d! R2 ~2 g; t! R
  |! z/ j2 t1 I4 p0 I' h6 b; n9 u
In many of the studies in which cells were transfected with either the ETA receptor or one of the inactive receptors, baseline NHE3 activity was observed to be increased, compared with cells transfected with the ETB receptor or a functional receptor. One possible explanation for this observation is that the vacant ETA receptor stimulates NHE3 activity and/or the vacant ETB receptor inhibits NHE3 activity, both effects due to binding of a NHE3-regulatory protein. Binding of ET-1 to these receptors could then inhibit binding of the regulatory protein, relieving NHE3 regulation. Thus binding of ET-1 to the ETB receptor may prevent NHE3 inhibition and/or binding of ET-1 to the ETA receptor may prevent NHE3 stimulation by the vacant receptor.
6 Z( m" N8 p5 _! T  @
; i8 K. r& k. ~- NReceptors have two functions, ligand recognition and binding ("address" function) and signal transmission ("message" function). Ligand binding studies have proposed that the region of transmembrane helices IV-VI and the adjacent loops of the ETA and ETB receptors determine the selection of ligand-receptor interaction and thus are considered to be the address recognition subdomain (33). In the case of the ETA receptor, this region matches more closely to the NH2 terminus (address domain) of ET-1 compared with ET-3, and thus ETA binds ET-1 with higher affinity than ET-3 (33). Subtle differences in the ETB receptor allow the address recognition domain to interact with a wider spectrum of ligand address domains, making the ETB receptor more promiscuous (33). The COOH-terminal portion of the ligand interacts with transmembrane helices I, II, III, and VII of the ETA and ETB receptors to transmit the ligand message (22). The present studies demonstrate that the amino acid sequence in the second intracellular loop and first part of transmembrane helix IV transmit the signal mediating ET-1 stimulation of NHE3 activity. The combination of a required repeat sequence, required spacing between essential amino acid residues, and a required proline residue between the repeat sequences suggests that the protein that binds the receptor might have symmetrical "arms" that interact with the receptor. Such a protein could be either a single protein or a homodimer.0 k) f4 e& o. I4 @' T* o' Q( E) W# I
. ^$ o" u4 X# w. i2 S" }& u
In summary, the present studies identify the COOH-terminal tail and a sequence within the second intracellular loop of the ETB receptor that are necessary and sufficient to mediate ET-1 stimulation of NHE3 activity. The presence of a repeat sequence with specific space requirements and a required proline residue separating the repeat sequences suggests that signal transmission is mediated by the binding of a homodimeric protein to the receptor.
! U/ n  w3 x" @& R5 c. O4 w9 B/ S& s3 ^' a
GRANTS
( Z/ }5 F4 X: s( X! e. X' s, Q
+ ]4 e% o/ S/ `% n* S7 ?( P+ N) U7 F) }- oThese studies were supported by National Institutes of Health Grant DK-39298. M. Yanagisawa is an Investigator of the HHMI.
$ Y5 ]# V2 D' j$ S1 z, L, M; `/ t. K  s$ `0 ]' p4 H' b+ Q+ `& v
Present address of K. Laghmani: Institut National de la Santé et de la Recherche Médicale, Institut Biomedicale des Cordeliers, Paris, France.
% V+ Y" F1 e5 ]7 D6 p" L- ]
8 ]8 G, V7 k3 L: [% u/ n. \) oPresent address of R. J. Alpern: Yale School of Medicine, New Haven, CT 06520.
( |) \$ I* k: V+ M7 g3 w3 `
& u& E/ \' [8 {1 m, vACKNOWLEDGMENTS
1 w1 ]( i8 t: i2 r, g/ K5 s2 e$ A. m+ ~* r: X5 y0 j$ x( y
Technical assistance was provided by Kavita Mathi and Ebtesam Abdel-Salam.( C, Q* P2 A9 X9 x: N
4 J) ~9 z6 k5 r, ]: p5 m( L; l! g
FOOTNOTES) S, A, \( p' _2 m
/ L* h8 w, P' V0 t, t2 S) v: G+ j+ b
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.  c7 R" J# G' C. k7 H

8 P, L: i9 J& P' \P. A. Preisig and R. J. Alpern contributed equally to these studies.9 f, {. Z& {8 V/ u

% u- _( G$ P" s; hREFERENCES+ A; X. p- h  S" q

. L: F* i, n$ P! d- |2 sAlpern RJ. Renal acidification mechanisms. In: The Kidney, edited by Brenner BM. Philadelphia, PA: W. B. Saunders, 2000, p. 455–519.# k. v/ T7 i  r

7 c: p" A) I! pAmemiya M, Yamaji Y, Cano A, Moe OW, and Alpern RJ. Acid incubation increases NHE-3 mRNA abundance in OKP cells. Am J Physiol Cell Physiol 269: C126–C133, 1995.& X+ G" D0 G9 w4 h% C1 T/ n
+ s/ v( X( d# _1 e5 N2 R4 I+ C
Arai H, Hori S, Aramori I, Ohkubo H, and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348: 730–732, 1990.
9 S, b8 k0 |% R6 f# I6 V% w) K: }1 V, [; v: h3 O
Biemesderfer D, Pizzonia J, Abu-Alfa A, Exner M, Reilly R, Igarashi P, and Aronson PS. NHE3: a Na/H exchanger isoform of renal brush border. Am J Physiol Renal Fluid Electrolyte Physiol 265: F736–F742, 1993.
) s4 y$ N; Y) `' O( L) T8 S- {' O* X
Burstein ES, Spalding TA, and Brann MR. The second intracellular loop of the m5 muscarinic receptor is the switch which enables G-protein coupling. J Biol Chem 273: 24322–24327, 1998.
5 P3 H/ t; j+ A
  x  k( F2 M) |) y* LChang W, Pratt S, Chen TH, Bourguignon L, and Shoback D. Amino acids in the cytoplasmic C terminus of the parathyroid Ca2 -sensing receptor mediate efficient cell-surface expression and phospholipase C activation. J Biol Chem 276: 44129–44136, 2001.6 V) n3 O6 z; v

* n+ W! S, L9 Y$ R0 p8 @Chu TS, Peng Y, Cano A, Yanagisawa M, and Alpern RJ. EndothelinB receptor activates NHE-3 by a Ca2 -dependent pathway in OKP cells. J Clin Invest 97: 1454–1462, 1996.7 m" c7 ~7 m1 p" E# k2 b

- ]8 B3 t! ?0 _: `( T6 d# K" qChu TS, Tsuganezawa H, Peng Y, Cano A, Yanagisawa M, and Alpern RJ. Role of tyrosine kinase pathways in ETB receptor activation of NHE3. Am J Physiol Cell Physiol 271: C763–C771, 1996.
2 z7 n1 ~2 ~4 R* o6 ^$ t+ T6 H  t2 _, m9 M* d! R
Edwards RM, Trizna W, and Stack EJ. [125I]endothelin-1 binding to renal brush-border and basolateral membranes. Eur J Pharmacol 345: 229–232, 1998.& q9 O* k% v6 F: v6 g2 i

" U+ D  b/ @+ j) \! REiam-Ong S, Hilden SA, King AJ, Johns CA, and Madias NE. Endothelin-1 stimulates the Na /H  and Na /HCO3– transporters in rabbit renal cortex. Kidney Int 42: 18–24, 1992.
/ z. F) C  ]* j. z# `4 y6 l: y3 d0 o
Gomeza J, Joly C, Kuhn R, Knpfel T, Bockaert J, and Pin JP. The second intracellular loop of metabotropic glutamate receptor 1 cooperates with the other intracellular domains to control coupling to G- proteins. J Biol Chem 271: 2199–2205, 1996.
2 C! s% Y* {% ~$ [) z
- z' D# k  d$ UGuntupalli J and DuBose TD. Effects of endothelin on rat renal proximal tubule Na -Pi cotransport and Na /H  exchange. Am J Physiol Renal Fluid Electrolyte Physiol 266: F658–F666, 1994.6 C$ K8 k7 ]: A8 o* S+ v% R

- v( ^# v% u7 E/ L2 K8 N" U5 qHosoda K, Nakao K, Tamura N, Arai H, Ogi K, Suga S, Nakanishi S, and Imura H. Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem 267: 18797–18804, 1992.2 B, w, i, ~0 i

- S" b- w, i/ x- B/ uHu MC, Fan L, Crowder LA, Karim-Jimenez Z, Murer H, and Moe OW. Dopamine acutely stimulates Na /H  exchanger (NHE3) endocytosis via clathrin-coated vesicles. J Biol Chem 276: 26915, 2001.
, ?3 h3 i) l$ E1 l* E
: I: o: {1 v# \. UIida-Klein A, Guo J, Takemura M, Drake MT, Potts JT Jr, Abou-Samra A, Bringhurst FR, and Segre GV. Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity. J Biol Chem 272: 6882–6889, 1997.
+ s8 S, |/ X( C: d
. `. k1 B9 H3 h" ^0 lKedzierski RM and Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 41: 851–876, 2001.
+ |) u3 ~- W. m$ W( s& }  V3 m' j% a  l2 [6 T
Koshimizu TA, Tsujimoto G, Ono K, Masaki T, and Sakamoto A. Truncation of the receptor carboxyl terminus impairs membrane signaling but not ligand binding of human ETB endothelin receptor. Biochem Biophys Res Commun 217: 354–362, 1995.
4 Z6 W: h6 _6 @+ N* o" {3 f/ f; Z" y- N2 U5 p+ g6 k
Laghmani K, Preisig PA, and Alpern RJ. Role of endothelin in proximal tubule proton secretion and the adaptation to a chronic metabolic acidosis. J Nephrol 15, Suppl 5: S75–S87, 2002.( c6 U1 ]) A4 ]1 T" {' L
7 k6 l% x/ t0 L; d1 T$ k: y  u& v
Laghmani K, Preisig PA, Moe OW, Yanagisawa M, and Alpern RJ. Endothelin-1/endothelin-B receptor-mediated increases in NHE3 activity in chronic metabolic acidosis. J Clin Invest 107: 1563–1569, 2001.& r+ I* m5 U8 U( A
7 r9 b4 j, c! u, u9 F# S% t9 Q
Li S, Sato S, Yang X, Preisig PA, and Alpern RJ. Pyk2 activation is integral to acid stimulation of NHE3. J Clin Invest 114: 1782–1789, 2004.
1 r2 u3 j  v- V8 @6 M( @
2 A6 e8 q7 A$ g. s8 D5 b3 qMasaki T, Ninomiya H, Sakamoto A, and Okamoto Y. Structural basis of the function of endothelin receptor. Mol Cell Biochem 190: 153–156, 1999." W' t- W% w- p- C/ d3 S

4 o7 F9 R: l7 S9 J' I$ w& j8 LMoe OW, Miller RT, Horie S, Cano A, Preisig PA, and Alpern RJ. Differential regulation of Na/H antiporter by acid in renal epithelial cells and fibroblasts. J Clin Invest 88: 1703–1708, 1991.7 y4 _2 w  Y# J; `5 M# i0 }2 b
+ V' P! r* z4 T( T0 \. K
Montrose MH and Murer H. Polarity and kinetics of Na-H exchange in cultured opossum kidney cells. Am J Physiol Cell Physiol 259: C121–C133, 1990.
, b0 C* |0 g+ w: s" v7 m* `) Y' w7 ^
Moro O, Lameh J, Hgger P, and Sadée W. Hydrophobic amino acid in the i2 loop plays a key role in receptor G protein coupling. J Biol Chem 268: 22273–22276, 1993.
" M" D4 W" ^% q) }% G  y; e! \# J' a4 |
Nelson J, Bagnato A, Battistini B, and Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110–116, 2003.7 F' e  X: [7 ?+ L: C  q
" t# d: B$ C# s2 h% s3 x3 D
Peng Y, Amemiya M, Yang X, Fan L, Moe OW, Yin HL, Preisig PA, Yanagisawa M, and Alpern RJ. ETB receptor activation causes exocytic insertion of NHE3 in OKP cells. Am J Physiol Renal Physiol 280: F34–F42, 2001.
8 T2 k9 y: D! Q6 I# E% H* U: S3 v' F$ ]0 v
Peng Y, Moe OW, Chu TS, Preisig PA, Yanagisawa M, and Alpern RJ. ETB receptor activation leads to activation and phosphorylation of NHE3. Am J Physiol Cell Physiol 276: C938–C945, 1999.6 ~7 _% U) |7 ]- i% m
( `  T* Z" S- `/ q7 X6 M5 ~! O  u
Preisig PA, Ives HE, Cragoe EJ, Alpern RJ, and Rector FC Jr. Role of the Na/H antiporter in rat proximal tubule bicarbonate absorption. J Clin Invest 80: 970–978, 1987.
1 L/ K6 ?* p/ m3 q" n/ M
& N6 \* C" g3 Q' q3 ?% E$ b5 _Preisig PA and Rector FC Jr. Role of Na-H antiport in rat proximal tubule NaCl absorption. Am J Physiol Renal Fluid Electrolyte Physiol 255: F461–F465, 1988.
. \$ Y% i& w. n, k
- j+ O  ^( L6 Z) V2 W0 h) K  A  HRabelink TJ, Kaasjager KAH, Stroes EG, and Koomans HA. Endothelin in renal pathophysiology: from experimental to therapeutic application. Kidney Int 50: 1827–1833, 1996.
* N2 D. q6 I4 m# U" Y
3 I4 h& N# ?, i8 WSakamoto A, Yanagisawa M, Sakurai T, Takuwa Y, Yanagisawa H, and Masaki T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun 178: 656–663, 1991.
' m8 ^# a0 a6 U  T, m  a5 V1 ~
# R( m3 J# l0 C: iSakamoto A, Yanagisawa M, Sawamura T, Enoki T, Ohtani T, Sakurai T, Nakao K, Toyo-oka T, and Masaki T. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. J Biol Chem 268: 8547–8553, 1993.0 r# ^9 i4 L( r3 @. w
0 {( x, l' f9 V, M
Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, and Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348: 732–735, 1990." j' ?4 m; g* q* s3 l2 M6 I

+ S+ F3 h7 W7 J0 ?9 HSimonson MS. Endothelins: multifunctional renal peptides. Physiol Rev 73: 375–411, 1993.
, y6 j0 C4 Z  G  {
3 t# e* B7 r4 B7 b, V7 V/ W9 yTakagi Y, Ninomiya H, Sakamoto A, Miwa S, and Masaki T. Structural basis of G protein specificity of human endothelin receptors: a study with endothelin A/B chimeras. J Biol Chem 270: 10072–10078, 1995.1 K( e+ ?$ W3 P. W' ]4 S

# a; W3 V+ v# K0 k: f: c3 STerada Y, Tomita K, Nonoguchi H, and Marumo F. Different localization of two types of endothlin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest 90: 107–112, 1992.
+ [2 e2 }$ u1 j* n. t
0 e8 ^- s9 {  r9 Y/ ]5 JThompson JB, Wade SM, Harrison JK, Salafranca MN, and Neubig RR. Cotransfection of second and third intracellular loop gragments inhibit angiotensin AT1a receptor activation of phospholipase C in HEK-293 cells. J Pharmacol Exp Ther 285: 216–222, 1998.2 K) |+ m6 {) H6 [' j8 y
9 K; v* B. ?- ~/ e- H. w; h
Tsuganezawa H, Preisig PA, and Alpern RJ. Dominant negative c-Src inhibits angiotensin II induced activation of NHE3 in OKP cells. Kidney Int 54: 394–398, 1998.
/ `5 ?. D6 S- W8 |
! h% ]% y" V) w- u0 j9 wTsuganezawa H, Sato S, Yamaji Y, Preisig PA, Moe OW, and Alpern RJ. Role of c-Src and ERK in acid-induced activation of NHE3. Kidney Int 62: 41–50, 2002.
- O; K8 l( J. K2 Y- y% D% y
/ @. u+ L2 X" k* q6 w/ xVerrall S, Ishii M, Chen M, Wang L, Tram T, and Coughlin SR. The thrombin receptor second cytoplasmic loop confers coupling to Gq-like G proteins in chimeric receptors. J Biol Chem 272: 6898–6902, 1997.
* G4 S  ^" |. q0 J6 R
! y$ G4 t; S. N8 ?! z" Z/ mYamamoto T and Uemura H. Distribution of endothelin-B receptor-like immunoreactivity in rat brain, kidney, and pancreas. J Cardiovasc Pharmacol 31, Suppl 1: S207–S211, 1998.(Kamel Laghmani, Aiji Saka)

Rank: 2

积分
70 
威望
70  
包包
1809  
沙发
发表于 2015-6-7 14:59 |只看该作者
昨天没来看了 ~~  

Rank: 2

积分
77 
威望
77  
包包
1964  
藤椅
发表于 2015-6-14 03:07 |只看该作者
对不起,我走错地方了,呵呵  

Rank: 2

积分
69 
威望
69  
包包
1788  
板凳
发表于 2015-7-16 13:27 |只看该作者
干细胞之家微信公众号
我卷了~~~~~~~  

Rank: 2

积分
116 
威望
116  
包包
1832  
报纸
发表于 2015-7-18 22:06 |只看该作者
又看了一次  

Rank: 2

积分
166 
威望
166  
包包
1997  
地板
发表于 2015-7-28 13:27 |只看该作者
加油啊!!!!顶哦!!!!!  

Rank: 2

积分
101 
威望
101  
包包
1951  
7
发表于 2015-7-30 16:27 |只看该作者
病毒转染干细胞

Rank: 2

积分
69 
威望
69  
包包
1788  
8
发表于 2015-8-6 21:54 |只看该作者
谁都不容易啊 ~~  

Rank: 2

积分
129 
威望
129  
包包
1788  
9
发表于 2015-8-7 09:18 |只看该作者
强人,佩服死了。呵呵,不错啊  

Rank: 2

积分
73 
威望
73  
包包
1833  
10
发表于 2015-8-10 09:27 |只看该作者
干细胞库  
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册
验证问答 换一个

Archiver|干细胞之家 ( 吉ICP备2021004615号-3 )

GMT+8, 2024-5-7 22:36

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.